Article

Cancer Suppressing Gene Actually Spreads Colorectal Cancer

Author(s):

Sprouty 2 gene works differently in colorectal cancer than in other types of cancers.

The gene Sprouty 2, previously thought to subdue the growth of cancer, has actually been found to speed up the spread of colorectal cancer.

“The gene known as Sprouty 2 has previously been shown to protect against metastasis, or the spreading of cancer to other parts of the body, in breast, prostate, and liver cancer. However, our recent molecular studies found that this gene may actually help promote metastasis instead of suppress it," said Sharad Khare, PhD, associate professor of research, University of Missouri School of Medicine’s Division of Gastroenterology and Hepatology.

For a three-year period, Khare and colleagues analyzed Sprouty 2 in cancer cell models, mouse models, and human biopsy samples.

The team noticed Sprouty 2 worked differently in colorectal cancer than in the other types of cancers. While Sprouty 2 was known to block molecular circuits to prevent cancer cells from spreading, the researchers found that in colorectal cancer, the gene was increasing the metastatic ability rather than quelling it — something that often occurs when the gene is up-regulated or supercharged.

“This finding is a very significant step in our understanding of metastasis in colorectal cancer, but it’s important to note that we believe this phenomenon may occur in only a subset of colorectal cancer patients," Khare said. "We don’t yet know why this is the case, but we hope to determine if there is a correlation between the up-regulation of this gene and the life expectancy of patients with colorectal cancer. Future studies will help us understand who may be at risk, and ultimately, if personalized treatments can be planned to target this gene.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards